Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759
ATX
0.205
210.6%
ASR
0.001
-50%
AR9
0.22
161.9%
CLG
0.023
-45.2%
IFG
0.011
120%
BCB
0.18
-44.6%
NHE
0.019
72.7%
AMI
0.205
-33.9%
NPM
0.019
72.7%
FCT
0.01
-33.3%
PV1
0.015
66.7%
RDN
0.004
-33.3%
JAV
0.003
50%
SRJ
0.004
-33.3%
PVT
0.009
50%
ICE
0.058
-31%
VR8
0.021
50%
DRE
0.009
-30.8%
SRL
0.73
47.5%
AON
0.005
-28.6%
FMR
0.3
46.3%
RPG
0.044
-26.7%
AHN
0.007
40%
FHS
0.003
-25%
AM5
0.007
40%
LKY
0.062
-22.5%
FDR
0.091
40%
AUG
0.021
-22.2%
EUR
0.061
38.6%
IR1
0.105
-22.2%
VMT
0.085
37.1%
MML
0.021
-22.2%
EVR
0.008
33.3%
ACM
0.06
-22.1%
LU7
0.008
33.3%
CC9
0.054
-21.7%
NAE
0.004
33.3%
JNS
0.15
-21.1%
SIS
0.004
33.3%
WTM
0.26
-20.5%
